DGAP-News: Sangui BioTech International Inc.: SastoMed gains top-class Granulox distribution partner in Southeast Europe
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Alliance
Sangui BioTech International Inc.: SastoMed gains top-class Granulox
distribution partner in Southeast Europe
16.07.2013 / 12:00
---------------------------------------------------------------------
Sangui BioTech: SastoMed gains top-class Granulox distribution partner in
Southeast Europe
Witten, Germany, July 16, 2013 - MEDiLAB c.o.o., Zagreb, Croatia,
undertakes the distribution of the wound therapeutic Granulox in Slovenia,
Croatia, Serbia, Bosnia and Herzegovina as well as Macedonia with a
combined population of over 20 million inhabitants. A contract to this
effect was now signed with global licensee SastoMed GmbH. MEDiLAB was
established in 1991 and employs more than 120 employees in its three
operating units. The company which has repeatedly obtained excellence
awards represents companies such as B. BRAUN, BAYER Diabetes Care, Siemens
MSD, Diesse and Buhlmann. It is renowned for its close cooperation with
professionals, medical doctors of various specialties, nurses and
pharmacists. As a first key step in Granulox promotion MEDiLAB intends to
create opportunities for specialist doctors to obtain positive experiences
through direct use of the product. Promotion is beginning these days while
actual sale to consumers will begin at the end of this year.
'We believe that Granulox is a real gem in a line of our key products',
emphasized MEDiLAB founder and General Manager Marko DŽepina. 'Its unique
performance demands and deserves intensive work with leading experts in
chronic wounds management, as well as a position in therapy algorithms of
chronic wounds treatment. We believe that its compatibility with our
existing products brings added value to our company business activities,
both in the eyes of medical professionals and in the financial plan. In
cooperation with business partners from the region we plan to change the
image of chronic wounds management market in the region.'
Michael Sander, Managing Director of SastoMed GmbH, confirms: 'We esteem
MEDiLAB a very dynamic enterprise, which excels in proactivity, creativity,
diligence and reliability. It ranks among the most successful mid-size
companies in its home markets. In addition it has a wide experience in
diabetes treatment and hence in chronic wounds. We are looking forward to
closely cooperating in the interest of the patients and of both partners.'
'It is all but an easy task to identify and contract top-class partners
such as MEDiLAB', adds Hubertus Schmelz, Director of Sangui BioTech
International, Inc. 'We do appreciate that SastoMed applies high standards
in its search for international distribution partners. Internationalization
from our point of view is one decisive lever to widely establish Granulox
in the wound management markets and to harvest the expected business
success.'
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
End of financial news
---------------------------------------------------------------------
16.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
221361 16.07.2013
Themen in dieser Pressemitteilung:
sangui-biotech-international-inc-sastomed-gains-top
class-granulox-distribution-partner-in-southeast-europe
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Destiny Media Technologies, Inc. Announces Fiscal 2013 Third Quarter Results
Datum: 16.07.2013 - 12:00 Uhr
Sprache: Deutsch
News-ID 278625
Anzahl Zeichen: 4565
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 323 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc.: SastoMed gains top-class Granulox distribution partner in Southeast Europe"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
